Whether ribociclib (Calilon) must be taken continuously for three years and the impact of long-term treatment on breast cancer patients

Ribociclib is an oral selective CDK4/6 inhibitor, mainly used to treat HRpositive, HER2negative advanced or metastatic breast cancer patients. It inhibits the activity of key cell cycle proteins CDK4 and CDK6, preventing cancer cells from entering the S phase from the G1 phase, thereby slowing down tumor proliferation. As a targeted therapy, ribociclib is often used in combination with endocrine therapy to improve efficacy and prolong progression-free survival.

As to whether it must be taken continuously for three years, current clinical guidelines and trial data do not require a fixed course of treatment. The use of ribociclib is mainly adjusted individually based on the patient's tolerance, efficacy and disease progression. Generally speaking, as long as the patient tolerates the drug and the tumor is well controlled, the drug can be continued until disease progression or intolerable adverse reactions occur. Therefore, there is no uniform requirement for "three-year use", and the treatment cycle should be flexibly determined based on clinical evaluation and monitoring results.

Long-term use of ribociclib may cause certain adverse reactions, including hematological toxicity such as neutropenia, anemia, abnormal liver function, and prolongation of QT interval. During long-term medication, patients need to undergo regular blood routine, liver and kidney function and electrocardiogram monitoring in order to detect abnormalities in a timely manner and adjust the dosage or temporarily discontinue the medication. These measures help reduce drug safety risks while ensuring efficacy.

In general, long-term treatment with Ribociclib (Ribociclib) has significant effects on breast cancer patients, and can delay tumor progression and improve quality of life. However, whether to take it continuously for three years should be determined based on the patient's individual situation and tolerance. Patients need to communicate closely with their attending doctors, regularly monitor efficacy and safety, and make treatment course adjustments under the guidance of doctors to maximize treatment benefits.

Keyword tags: ribociclib,CDK4/6inhibitor, breast cancer, targeted therapy, long-term medication

Reference materials:https://pmc.ncbi.nlm.nih.gov/articles/PMC12464853/